All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | Allele | Vector Type | Inquiry & Datasheet |
TCR-YC0980 | Human anti-PIGN T cell receptor (AA8), pCDTCR1 | AA8 | Human | FLTVFSHFM | HLA-A2 | Lentiviral vector | ||
TCR-YC0981 | Human anti-PIGN T cell receptor (AH6), pCDTCR1 | AH6 | Human | FLTVFSHFM | HLA-A2 | Lentiviral vector | ||
TCR-YC0982 | Human anti-PIGN T cell receptor (BC10), pCDTCR1 | BC10 | Human | FLTVFSHFM | HLA-A2 | Lentiviral vector | ||
TCR-YC0983 | Human anti-PIGN T cell receptor (BG5), pCDTCR1 | BG5 | Human | FLTVFSHFM | HLA-A2 | Lentiviral vector | ||
TCR-YC0984 | Human anti-PIGN T cell receptor (FG9), pCDTCR1 | FG9 | Human | FLTVFSHFM | HLA-A2 | Lentiviral vector | ||
TCR-YC0985 | Human anti-PIGN T cell receptor (GB11), pCDTCR1 | GB11 | Human | FLTVFSHFM | HLA-A2 | Lentiviral vector | ||
TCR-YC0986 | Human anti-PIGN T cell receptor (JA5), pCDTCR1 | JA5 | Human | FLTVFSHFM | HLA-A2 | Lentiviral vector | ||
TCR-YC0987 | Human anti-PIGN T cell receptor (LD4), pCDTCR1 | LD4 | Human | FLTVFSHFM | HLA-A2 | Lentiviral vector | ||
TCR-YC0988 | Human anti-PIGN T cell receptor (LD6), pCDTCR1 | LD6 | Human | FLTVFSHFM | HLA-A2 | Lentiviral vector | ||
TCR-YC0989 | Human anti-PIGN T cell receptor (LG11), pCDTCR1 | LG11 | Human | FLTVFSHFM | HLA-A2 | Lentiviral vector | ||
TCR-YC0990 | Human anti-PIGN T cell receptor (LH5), pCDTCR1 | LH5 | Human | FLTVFSHFM | HLA-A2 | Lentiviral vector | ||
TCR-ZP467 | Human anti-PIGN T cell receptor (MC5), pCDTCR1 | Human | MC5 | Human | FLTVFSPFM | HLA-DRB5 | Lentiviral vector |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION